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Aim: To evaluate the effectiveness of the addition of epirubicin to conventional chemotherapy as a first-line therapy for stage III–IV
epithelial ovarian cancer.
Materials and methods: A total of 132 patients who had undergone primary cytoreductive surgery between January 1998 and March
2003 were enrolled in the study. Twenty-four cases were excluded. Out of the remaining 108 subjects, 35 received epirubicin/paclitaxel/
carboplatin (Group EPC) and 73 were treated with paclitaxel/platinum (cisplatin or carboplatin) (Group PC).
Results: The median follow-up period was 66.5 months. The clinical complete response was 94% in the EPC group and 97% in the PC
group. The recurrence rate in the first 6 months after treatment was significantly higher in the PC than the EPC group (47% vs. 23%, P =
0.018). Triplet chemotherapy was not found to improve 2- and 5-year disease-free survival (DFS) statistically. No significant difference
in overall survival was observed between the 2 groups (80% vs. 83% at 2 years and 56% vs. 57% at 5 years for the PC and the EPC group,
respectively). The main toxicity in both groups was hematological, and it was particularly severe in the EPC group.
Conclusion: The addition of epirubicin to the standard treatment protocol yielded an improvement in the DFS rate that was not
statistically significant and caused a tolerable increase in toxicity.
Key words: Epithelial ovarian cancer, gynecological oncology, chemotherapy

1. Introduction
Improved chemotherapeutic protocols have increased the
5-year survival rate for ovarian cancer, which rose from
37% in the mid-1970s to 53% in the late 1990s (1). While
the chemotherapy protocols in the 1970s were composed of
chemotherapeutics basically containing alkylating agents,
particularly cyclophosphamide, by the 1980s platinumbased chemotherapy became more common. In a study of
the Gynecologic Oncology Group, the cyclophosphamide
and cisplatin combination was compared with paclitaxel
(taxane derivative) and cisplatin, and it was reported
that paclitaxel improved survival in the patients with
incompletely resected advanced-stage epithelial ovarian
cancer (2). After the 1990s, combined paclitaxel and
platinum-based (carboplatin or cisplatin) chemotherapy
has been generally accepted as the preferred chemotherapy
regimen for ovarian carcinoma.
* Correspondence: isin.ureyen@gmail.com
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The standard treatment procedure in epithelial ovarian
cancer consists of optimal or suboptimal cytoreductive
surgery followed by 6 cycles of taxane and platinum
combination chemotherapy. The total response rate
obtained with this treatment is 70%–80% (2,3). However,
patients who respond to this initial treatment suffer a
recurrence rate of 50%–75% within 18 to 28 months
(4). The response rate of second-line chemotherapy for
recurrent cases is very low, with reported rates ranging
between 10% and 25% (5,6).
These treatment failures in ovarian cancer have
inspired research into new treatment options, including
the addition of a third drug to the chemotherapy
regimen. The third agent can be applied as consecutive
chemotherapy (7), consolidation chemotherapy (8), or
combination chemotherapy. Combination chemotherapy
has been most thoroughly studied. Drugs that have been
studied as a third agent include etoposide (9), topotecan
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(10), irinotecan (11), gemcitabine (12), and anthracyclines
such as doxorubicin (13).
In the Ovarian Cancer Meta-Analysis Project, 4
studies comparing the cyclophosphamide and cisplatin
combination
with
combined
cyclophosphamide,
doxorubicin, and cisplatin were reviewed, and the addition
of doxorubicin to the treatment protocol was reported to
reduce the mortality rate by 16% in the 10-year follow-up
period (14).
Subsequent studies showed that epirubicin, an
anthracycline derivative of doxorubicin, had anticancer
effects that were equivalent to those of doxorubicin with
less cardiac and other toxicities (15). It is critical to ensure
that any drug considered as a third agent is demonstrated
to show no cross-reactivity with the other 2 drugs, taxane
and platinum-based drugs, in the protocol, and that the
third agent acts via a different mechanism. In theory,
epirubicin fulfills both of these criteria, since paclitaxel
acts by stabilizing microtubule formation to prevent their
depolarization and carboplatin binds to DNA to inhibit its
synthesis, while epirubicin prevents DNA from forming a
double helix by binding to nucleic acids and inhibiting the
topoisomerase I and II enzymes.
In this study, the standard chemotherapy combination
of paclitaxel and platinum (carboplatin or cisplatin) was
compared with a triple chemotherapy combination consisting
of epirubicin, paclitaxel, and carboplatin, with the specific
objective of evaluating the effect of epirubicin on survival and
toxicity in patients with epithelial ovarian cancer.
2. Materials and methods
One hundred and thirty-two subjects who all underwent
cytoreductive surgery followed by chemotherapy between
the years 1998 and 2003 for advanced ovarian cancer were
enrolled in this study.
2.1. Patients’ eligibility
Patients were considered for enrollment if they had
histologically proven stage III or IV epithelial ovarian
cancer according to the International Federation of
Gynecology and Obstetrics (FIGO) staging system
following optimal or suboptimal surgery (16).
2.2. Chemotherapy schedule
One group received paclitaxel with cisplatin (Group PCcis; n = 34), the second group received paclitaxel with
carboplatin (Group PC-cb; n = 39), and the third group
(Group EPC; n = 35) was given epirubicin, paclitaxel, and
carboplatin.
In Group PC, treatment started with paclitaxel (175
mg/m2 in 500 mL of 0.09% NaCl solution infused over 3
h), followed either by carboplatin (calculated according to
AUC = 6, infused in 1000 mL of 5% dextrose solution over
1 h) or cisplatin (75 mg/m2 infused in 1000 mL of normal
saline solution over 2 h with 500 mL of 20% mannitol).

Patients in Group EPC were given epirubicin (60 mg/m2
in 250 mL of 5% dextrose infused over 2 h), followed by
paclitaxel (175 mg/m2) and then carboplatin (AUC = 6).
Before chemotherapy was given, the following criteria
were met: 1) adequate bone marrow function [white
blood cell (WBC) count ≥3000/mL, neutrophils ≥1500/
mL, platelets ≥100,000/mL, hemoglobin ≥10 mg/dL];
2) adequate hepatic function [total bilirubin, aspartate
transferase (AST), and alanine transaminase (ALT) of less
than twice normal levels]; and 3) sufficient renal function
(glomerular filtration rate ≥60 mL/min).
Treatment was administered every 21 days. Patients
received chemotherapy premedication, with an oral
dose of 20 mg of dexamethasone and an H2 receptor
antagonist, both 14 h and 7 h prior to chemotherapy,
as well as an intravenous administration of both an H1
receptor antagonist and a 5-HT3 receptor antagonist 1 h
before chemotherapy. Patients did not receive granulocyte
colony-stimulating factor or erythropoietin prophylaxis.
Hematology and biochemistry tests (WBC, hemoglobin,
platelets, urea, creatinine, AST, ALT, and total bilirubin)
were done every 10th day after each cycle to assess each
patient’s ability to tolerate the chemotherapy regimen and
to detect potential toxicity, which was assessed according to
the World Health Organization criteria and was evaluated
per patient and per cycle (17). An electrocardiogram was
taken before the first cycle of chemotherapy.
2.3. Second-look laparotomy
Before 2003, a second-look laparotomy (SLL) procedure
was offered and performed for the patients with epithelial
ovarian cancer in our clinic.
After 6 courses of chemotherapy, patients who were
in complete clinical remission according to the imaging
methods and who had a CA-125 value of not greater than
35 IU/mL were offered SLL to evaluate the effectiveness of
chemotherapy. If the patient accepted, SLL was performed
within 6 weeks of the end of chemotherapy and consisted
of exploration of the abdomen via a midline incision
allowing access to the upper abdomen. Cytology samples
were collected from ascites or peritoneal washing fluid.
Any adhesions were separated with sharp and blunt
dissection to enlarge the observation field, and were
themselves biopsied. All peritoneal surfaces were carefully
checked and then biopsied, as were the serosal surfaces
of the bowel. Any suspicious region was resected. Biopsy
samples were taken from any areas of the retroperitoneum
that appeared suspicious; otherwise, random biopsies were
taken. All samples were examined intraoperatively by
frozen section. The mean number of samples taken during
the surgical procedure was 30. Secondary cytoreduction
was performed for the patients who were found to have a
gross tumor at SLL. Salvage chemotherapy was applied in
cases with a proven disease after SLL.
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The effectiveness of each chemotherapy regimen
was evaluated based on both SLL results and survival.
Both 2-year and 5-year disease-free survival (DFS) and
overall survival (OS) results were analyzed. At first, the
3 groups were compared with each other. After that, data
of the PC-cis and PC-cb groups were combined into one
group, named Group PC. Group PC and Group EPC were
compared to each other for survival rates.
Since carboplatin and cisplatin are known to have
different toxicity profiles, the cisplatin arm (PC-cis
subgroup) of Group PC was excluded from toxicity
assessment, leaving a total of 74 patients to be evaluated.
One researcher carried out all toxicity assessments. The
toxicity rates were compared between the 2 groups (Group
PC vs. Group EPC). Kaplan–Meier survival analysis, an
analysis of variance table test, and a chi-square test were
used for statistical analysis. The cut-off for statistical
significance was set at P < 0.05.

3. Results
Twenty-four of the 132 patients who met the inclusion
criteria and who were enrolled in the study were later
excluded from the study. Among these, 15 patients
failed to present for follow-up after chemotherapy or
SLL, 3 patients had a second malignancy, 3 patients
gave up chemotherapy (after the 1st, 2nd, and 5th cycle,
respectively), 1 patient died because of reasons unrelated
to the disease, 1 patient had a primary malignancy that
could not be defined with certainty, and in 1 case the
interval between consecutive cycles of chemotherapy
exceeded 6 weeks.
The median age of the remaining 108 patients was
51.6 years (range: 20–71). Details of the diagnosis and
treatment for the patients in each study group are shown
in Table 1. There was no statistically significant difference
among the groups except for mean age, which was lower in
the EPC group (Table 1).

Table 1. The characteristics of the patients according to chemotherapy regimens.
Characteristics

Group EPC,
mean (median; range)
(n = 35)

Group PC, mean
(median; range)
(n = 73)

P

Age (years)

47.6 (48; 20–68)

53.6 (54; 23–71)

0.005*

CA 125 (U/mL)

1244 (416; 8–2500)

658 (432; 7–5950)

0.310

III

35

69

IV

-

4

Serous

29

60

Endometrioid

4

5

Mucinous

1

1

Mix

-

4

Unclassified

1

3

1

7

5

Stage

Cell type

Grade

0.158

0.575

2

16

38

3

12

30

Negative

10

16

Positive

25

57

Optimal

35

66

Suboptimal

-

7

Not performed

8

19

Performed

27

54

Follow-up (months)

61.3 (62; 3–130)

66.9 (74; 5–113)

0.467

Time to recurrence (months)

21.5 (12; 1–95)

9.7 (3;1–95)

0.012*

Time to death (months)

42.4 (38; 5–108)

37.5 (31; 3–87)

0.441

Peritoneal cytology
Cytoreductive surgery
Second look laparotomy

*: Statistically significant.

214

0.125

0.466
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Group EPC included 35 subjects and Group PC
contained 73 subjects (39 in the PC-cb subgroup and 34 in
the PC-cis subgroup). The optimal cytoreductive surgery
rate and mean follow-up period were similar in these
groups (Table 1). A total of 654 chemotherapy cycles were
assessed.
3.1. Survival analysis
Among the 108 patients included in the study, 5 were lost to
follow-up at 18, 20, 22, 48, and 60 months of the treatment,
respectively. All these patients were in the PC group: 3 in
PC-cb and 2 in PC-cis. Among these 5 patients, 4 patients
underwent SLL. In the 3rd and 4th patients there were
findings of disease. The remaining 3 patients in this group
suffered from recurrence (at 5, 9, and 14 months after the
last cycle of treatment). Since each of the 5 patients were
included in the DFS analysis, the 4th was also included in
the 2-year OS and the 5th was also included in the 5-year
OS analysis.
The clinical complete response rates were similar
between the 2 groups (94% in Group EPC and 97% in
Group PC, P = 0.443). SLL was offered to 103 patients who
achieved clinical complete response and it was performed
for 81 patients (15 patients refused, and SLL could not be
performed for 7 patients because of medical problems).
In 43% of patients in the PC group and 22% of patients
in the EPC group, SLL revealed residual disease (P =
0.051). Thereby, the histopathological response rate was
78% and 57% for triplet chemotherapy and the standard
treatment modality, respectively. This difference reached
only borderline statistical significance.

Seventy-eight patients (72.2%) had recurrence at a
mean interval of 13.5 months. Recurrence within the
first 6 months after chemotherapy was significantly more
common in the PC group than the EPC group (47% vs.
23%, respectively; P = 0.018). The time elapsed between
therapy and recurrence was significantly longer in Group
EPC than in Group PC (P = 0.012). Sixty patients died
(55.6%), with a mean of 39.2 months between the end of
treatment and death. Within the EPC group, the mean time
between treatment and death was 42.4 months (median:
38; range: 5–108), compared to 37.5 months in Group PC
(median: 31; range: 3–87; P = 0.441) (Table 1).
Two- and 5-year survival were compared both among
the subgroups (PC-cb vs. PC-cis, PC-cb vs. EPC, and
PC-cis vs. EPC) and between the 2 main groups (PC vs.
EPC). Although DFS rates at 2 and 5 years were lower and
the OS rates were higher when the PC-cis subgroup was
compared with the PC-cb subgroup, these differences were
not statistically significant (Table 2).
There was no statistically significant difference in
survival rates between Group EPC and either of the 2
subgroups.
When the 2 main groups were compared, triplet
chemotherapy did not provide statistically significant
improvement in 2- and 5-year survival rates. However,
the triplet chemotherapy group had an approximately
15% greater 2-year DFS (P = 0.118; Table 2). At the end
of 5 years, this improvement fell to 8% (P = 0.380). The
improved DFS rates obtained with triplet chemotherapy
were not observed in OS (P = 0.725 and 0.952 for 2- and
5-year OS, respectively).

Tablo 2. Two- and 5-year survival rates according to chemotherapy regimens.
Chemotherapy

2-year survival
DFS (%)
†

5-year survival
OS (%)
‡

DFS† (%)

OS‡ (%)

Group PC-cb

41

78

32

52

Group PC-cis

31

82

26

60

p

0.354

0.719

0.527

0.516

Group PC-cb

41

78

32

52

Group EPC

51

83

37

57

p

0.393

0.625

0.676

0.652

Group PC-cis

31

82

26

60

Group EPC

51

83

37

57

p

0.071

0.887

0.286

0.842

Group PC

36

80

29

56

Group EPC

51

83

37

57

p

0.118

0.725

0.380

0.952

DFS; Disease-free survival,

†

‡

OS; Overall survival
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3.2. Toxicity
The most common toxicity in both groups (Groups PC
and EPC) was hematologic. Grade 3–4 neutropenia and
anemia were more common in Group EPC in terms of both
the number of patients and the number of cycles (Table
3). No difference in thrombocytopenia was seen between
the EPC and PC-cb subgroups. Grade 3–4 neutropenia
was seen in 36% of the cycles in Group EPC and in only
12% of the cycles in Group PC-cb. Febrile neutropenia
was observed only in Group EPC. Febrile neutropenia was
observed in 3 patients (8.6%) in a total of 5 cycles (2.4%). It
occurred in the 2nd cycle in 2 patients and in the 5th cycle
in the remaining patient. In 2 patients, the second episode
of febrile neutropenia was observed in the consecutive
cycle.
No grade 4 toxicity was observed aside from
hematologic toxicity. However, grade 3 hepatic, renal, and
gastrointestinal system toxicity were seen (Table 3). Nausea,
vomiting, and diarrhea were more common in Group EPC.
All patients suffered from at least grade 2 alopecia. Grade
3 alopecia was particularly marked in Group EPC (Table
3). Neuropathy, pain, and constipation rates were similar
between the 2 groups. The neuropathy was not of sufficient
severity to affect the patients’ daily lives.
No patient died, no patient discontinued chemotherapy,
and no patient required dose reduction due to toxicity.
However, delays between cycles of chemotherapy did
occur. The delay rate per patient and per cycle was higher
in Group EPC, although it was not statistically significant.
While the chemotherapy cycles per person were delayed in
34% of patients in Group EPC, this rate was 37% in Group
PC (20% in PC-cb, 17% in PC-cis; P = 0.219). The delay
rates per cycle were 7% in Group EPC and 8% in Group
PC (5% in PC-cb, 3% in PC-cis; P = 0.309). Hematologic
toxicity was the most common cause for delay of
chemotherapy cycles. Thirteen of the 14 cycle delays that
occurred in Group EPC were caused by hematological
toxicity and the remaining 1 delay was because of hepatic
toxicity. In Group PC-cb, 10 delays were for hematological
reasons and 1 delay was due to hepatic toxicity. In Group
PC-cis, 4 delays were because of hematological reasons
and 3 delays were due to hepatic and renal toxicity.
4. Discussion
In this study, we found that although adding epirubicin
to standard treatment as a third agent yielded an
approximately 15% improvement in 2-year DFS and an 8%
improvement in 5-year DFS, it had no significant effect on
survival. This triple chemotherapy protocol also delayed
the occurrence of recurrence. Addition of epirubicin to
the standard treatment protocol significantly reduced the
rate of platinum resistance from 47% to 23%. The interval
between treatment and recurrence markedly increased
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from an average of 9.7 months to 21.5 months. Moreover,
the pathological complete response rate increased from
57% to 78% with addition of epirubicin. Nevertheless,
this effect reached only borderline statistical significance
(P = 0.051). Although there was an 8% improvement in
2-year OS, there was no apparent effect in 5-year OS. The
time interval between treatment and death was the same
in the groups treated with and without epirubicin and OS
was similar between the subgroups. As a result, long-term
follow-up revealed no advantage of epirubicin on survival.
The relative youth of patients in the EPC group might
explain the observed improvement in DFS.
DFS rates ranging between 16.4 and 19.5 months have
been reported for ovarian cancer treated with epirubicin,
paclitaxel, and either cisplatin or carboplatin (18–20). In
this study, there was an average of 21.5 months between the
end of treatment and the time of recurrence for patients in
Group EPC.
For triplet chemotherapy in which epirubicin is
added to first-line chemotherapy, clinical response rates
of over 80% have been reported, with complete response
rates between 33% and 64% (19,20). Romanini et al.
reported a pathological response rate of 27.3% when the
chemotherapy was given every 28 days (19). In the current
study, the clinical complete response rate with triplet
chemotherapy was 94% and the pathological complete
response rate was 78%, compared to 97% and 57% in
Group PC, respectively.
Kristensen et al. reported that the addition of
epirubicin to the standard treatment protocol for ovarian
cancer improved the complete response rate by 10%
(21). However, further analysis of those data revealed
that epirubicin had no effect on DFS time (22). Similarly,
Pujade-Lauraine et al. demonstrated that the addition of
epirubicin improved neither DFS nor OS rates (18).
Although side effects of the treatment were most
prominent in Group EPC, they were tolerated by the
patients and they were manageable for the physicians.
The most severe toxicity was hematologic, which
was responsible for 13 of the 14 delays in sequential
chemotherapy cycles. Aside from hematological toxicity,
no other grade 4 toxicity was encountered.
Epirubicin is commonly used at doses of 50, 60, or
75 mg/m2. Vermorken et al. used high-dose (150 mg/m2)
epirubicin as second-line chemotherapy in ovarian cancer.
Bone marrow depression, mucositis, nausea, and vomiting
were the main reported toxicities in that study, and one
patient died from toxic side effects (23).
The addition of epirubicin as a third agent to the
standard therapy is associated with neutropenia and
febrile neutropenia. Du Bois et al. reported that grade
3–4 neutropenia occurred in 52% of the cycles in which
epirubicin was administered at a dose of 60 mg/m2 and in
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Table 3. Toxicity rates in patients and cycles according to chemotherapy regimens.
Toxicity
Per person
Neutropenia

Hematologic toxicity

Per cycle

Per person
Anemia
Per cycle

Per person
Thrombocytopenia
Per cycle

Mucositis

Hepatic toxicity

Nausea and vomiting

Diarrhea

Proteinuria

Per cycle

Per cycle

Per cycle

Per cycle

Per cycle

Hematuria

Per cycle

Alopecia

Per person

Neuropathy

Per person

Pain

Per person

Constipation

Per person

Grade

Group EPC (%)

Group PC-cb (%)

0

-

13

1–2

26

54

3–4

74

33

0

22

44

1–2

42

44

3–4

36

12

0

-

31

1–2

77

69

3–4

23

-

0

31

65

1–2

64

35

3–4

5

-

0

63

79

1–2

26

18

3–4

11

3

0

85

95

1–2

12

4

3–4

3

1

0

67

61

1–2

29

35

3

4

4

0

95

89

1

4

9

2–3

1

2

0

43

71

1

40

22

2–3

17

7

0

85

89

1

8

2

2–3

7

9

0

90

92

1

9

5

2–3

1

4

0

94

93

1–2

6

7

2

3

18

3

97

82

0

17

3

1–2

83

97

0

-

5

1–2

100

95

0

34

44

1–2

66

56

P
<0.001*

<0.001*

0.001*

<0.001*

0.185

0.001*

0.394

0.068

0.001*

0.008*

0.267
0.148
0.037*
0.340
0.704
0.413

*: Statistically significant.
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60% of the cycles in which the dose was 75 mg/m2 (24). In
the current study, grade 3–4 neutropenia was significantly
more common in Group EPC, occurring in 36% of cycles.
The rate of febrile neutropenia has been reported between
5.5% and 17% (18,21,25). We observed febrile neutropenia
only in Group EPC, where it occurred in 8.6% of cycles.
Anemia was also markedly elevated in Group EPC, with
grade 3–4 anemia occurring in 5.2% of cycles, a rate similar
to that reported by du Bois et al. (3% and 4% for doses
of 60 mg/m2 and 75 mg/m2, respectively) (24). However,
the rates of grade 3–4 thrombocytopenia reported by du
Bois et al. (13% and 23% for doses of 60 mg/m2 and 75
mg/m2, respectively) were quite different from the rates

observed in the current study. Although, as in this study,
du Bois et al. encountered no grade 4 toxicity other than
hematological toxicity, other studies have reported grade 4
neuropathy and vomiting (18,21).
One limitation of this study was the small number
of patients. Therefore, use of epirubicin in triplet
chemotherapy in ovarian cancer should be explored in
further, multicenter studies.
In conclusion, the addition of epirubicin to the
standard treatment protocol yielded an improvement
in the DFS rate that was not statistically significant and
caused a tolerable increase in toxicity. Nevertheless, it did
not provide a clear benefit in survival.
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